Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
Authors:
Open Access
- 15 August 2024
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 75, 102777
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk UK Research Foundation
- Juvenile Diabetes Research Foundation United States of America
- University of Liverpool
This publication has 34 references indexed in Scilit:
- Obesity Management in AdultsJAMA, 2023
- A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage onMetabolism, 2022
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Why does obesity cause diabetes?Cell Metabolism, 2022
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialThe Lancet, 2021
- Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trialsNutrition, Metabolism and Cardiovascular Diseases, 2021
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialThe Lancet, 2021
- Benefits and Risks of Bariatric Surgery in AdultsJAMA, 2020
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Active-comparator design and new-user design in observational studiesNature Reviews Rheumatology, 2015